Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Institutul Regional de Gastroenterologie & Hepatologie Prof. dr. Octavian Fodor | OTHER |
Not provided
Not provided
Not provided
Not provided
Remimazolam is a new, ultra-short-acting benzodiazepine approved in Romania for procedural sedation. It shows significant clinical benefits compared to other sedatives like Propofol or Midazolam, especially in elderly or high-risk patients. Advantages include better hemodynamic stability, reduced respiratory depression, lower incidence of postoperative delirium, and rapid recovery without residual sedation. It is metabolized by liver esterases and is less affected by organ dysfunction. Clinical studies suggest that remimazolam may be a safer and more effective alternative in procedural and general anesthesia. The findings support the development of institutional protocols for its use, particularly in high-risk populations and endoscopic procedures.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Remimazolam | Active Comparator | Lot 1 - Participants in this arm will receive remimazolam for procedural sedation. Remimazolam will be administered intravenously according to the institutional sedation protocol, with dosing adjusted to achieve adequate procedural sedation. |
|
| Propofol | Active Comparator | Lot 2 - Participants in this arm will receive Propofol for procedural sedation. Propofol will be administered intravenously according to standard clinical practice, with dosing adjusted to achieve adequate procedural sedation. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Administering remimazolam | Drug | Administering Remimazolam for procedural sedation |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Heart rate (beats per minute) | The lowest heart rate will be recorded | Periprocedural |
| Mean arterial pressure (mmHg) | The lowest mean arterial pressure will be recorded | Periprocedural |
| Incidence of hypotension requiring vasoactive support (Yes/No) | The presence of hypotension requiring vasoactive drug administration will be recorded. | Periprocedural |
| Measure | Description | Time Frame |
|---|---|---|
| Patient satisfaction | Patient satisfaction will be recorded as a single score per participant. | Postprocedural |
| Endoscopist satisfaction (5-point Likert scale) | Endoscopist satisfaction will be evaluated and recorded as a single 5-point Likert score per participant. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Regional Institute of Gastroenterology-Hepatology Prof. Dr. Octavian Fodor | Cluj-Napoca | Cluj | Romania |
Due to the investigator-initiated nature of the study and local data protection regulations, individual participant data will not be made available for sharing.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009102 | Multiple Organ Failure |
| ID | Term |
|---|---|
| D012769 | Shock |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Administering propofol |
| Drug |
Administering Propofol for procedural sedation |
|
| Periprocedural |
| Quality of recovery (ordinal scale) | Quality of recovery will be assessed using an ordinal clinical scale and reported as a single score per participant. | Periprocedural |
| Incidence of postoperative nausea and vomiting (Yes/No) | The presence of nausea and/or vomiting will be recorded. | Periprocedural |
| Total dose of sedative administered (mg) | Total intravenous dose of the sedative agent administered during the procedure. | Periprocedural |
| Need for airway intervention due to apnea (Yes/No) | The need for airway support due to apnea will be recorded. | Periprocedural |
| Incidence of apnea (Yes/No) | The occurrence of apnea during procedural sedation will be recorded. | Periprocedural |
| Peripheral oxygen saturation (SpO₂,%) | Peripheral capillary oxygen saturation will be measured using pulse oximetry and summarized as the mean periprocedural value. | Periprocedural |
| Respiratory rate (breaths per minute) | Respiratory rate will be monitored during the periprocedural period. | Periprocedural |
| Duration of apnea (seconds) | Duration of apnea episodes will be measured in seconds. | Periprocedural |
| Need for change in sedation regimen (Yes/No) | The need to change the planned sedation regimen will be recorded. | Periprocedural |
| Incidence of postprocedural delirium (Yes/No) | Postprocedural delirium or agitation will be recorded. | Periprocedural |
| Incidence of adverse events (Yes/No) | The occurrence of adverse events related to procedural sedation will be recorded. | Periprocedural |